A team of researchers at the international firm, Takeda Vaccines, has announced the results of the first phase of trial testing a new vaccine to prevent dengue infections.
In their paper published in The New England Journal of Medicine, the researchers outlined their trial and how well the drug is working in test cases.
The researchers called their findings encouraging but remain cautious.
Children who were tested will continue to be watched and examined for four and a half more years.
If at that point, the numbers remain promising, the drug will become eligible for widespread use.
Prior efforts to create a vaccine have failed, however, due to a peculiarity of the dengue virus—it comes in four strains, and sometimes, being infected by one type makes a person more susceptible to a worse infection by another strain at a later date.